vs
Idexx Laboratories（IDXX）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
Idexx Laboratories的季度营收约是Rollins, Inc.的1.2倍（$1.1B vs $906.4M），Idexx Laboratories净利率更高（22.8% vs 11.9%，领先10.9%），Idexx Laboratories同比增速更快（14.3% vs 10.2%），Idexx Laboratories自由现金流更多（$326.3M vs $111.2M），过去两年Idexx Laboratories的营收复合增速更高（6.4% vs 0.8%）
IDEXX Laboratories是1983年成立的美国跨国企业，主营伴侣动物诊疗、畜禽养殖、水质检测、乳制品领域相关产品与服务的研发、生产及分销，总部位于缅因州韦斯特布鲁克，欧洲、中东及非洲地区分部设于荷兰霍夫多普。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
IDXX vs ROL — 直观对比
营收规模更大
IDXX
是对方的1.2倍
$906.4M
营收增速更快
IDXX
高出4.1%
10.2%
净利率更高
IDXX
高出10.9%
11.9%
自由现金流更多
IDXX
多$215.1M
$111.2M
两年增速更快
IDXX
近两年复合增速
0.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $906.4M |
| 净利润 | $248.2M | $107.8M |
| 毛利率 | 60.3% | — |
| 营业利润率 | 28.9% | 16.1% |
| 净利率 | 22.8% | 11.9% |
| 营收同比 | 14.3% | 10.2% |
| 净利润同比 | 14.8% | 2.5% |
| 每股收益（稀释后） | $3.09 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IDXXROL
| Q1 26 | — | $906.4M | ||
| Q4 25 | $1.1B | $912.9M | ||
| Q3 25 | $1.1B | $1.0B | ||
| Q2 25 | $1.1B | $999.5M | ||
| Q1 25 | $998.4M | $822.5M | ||
| Q4 24 | $954.3M | $832.2M | ||
| Q3 24 | $975.5M | $916.3M | ||
| Q2 24 | $1.0B | $891.9M |
净利润IDXXROL
| Q1 26 | — | $107.8M | ||
| Q4 25 | $248.2M | $116.4M | ||
| Q3 25 | $274.6M | $163.5M | ||
| Q2 25 | $294.0M | $141.5M | ||
| Q1 25 | $242.7M | $105.2M | ||
| Q4 24 | $216.1M | $105.7M | ||
| Q3 24 | $232.8M | $136.9M | ||
| Q2 24 | $203.3M | $129.4M |
毛利率IDXXROL
| Q1 26 | — | — | ||
| Q4 25 | 60.3% | — | ||
| Q3 25 | 61.8% | — | ||
| Q2 25 | 62.6% | — | ||
| Q1 25 | 62.4% | — | ||
| Q4 24 | 59.8% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 61.7% | — |
营业利润率IDXXROL
| Q1 26 | — | 16.1% | ||
| Q4 25 | 28.9% | 17.5% | ||
| Q3 25 | 32.1% | 21.9% | ||
| Q2 25 | 33.6% | 19.8% | ||
| Q1 25 | 31.7% | 17.3% | ||
| Q4 24 | 27.4% | 18.1% | ||
| Q3 24 | 31.2% | 20.9% | ||
| Q2 24 | 26.3% | 20.4% |
净利率IDXXROL
| Q1 26 | — | 11.9% | ||
| Q4 25 | 22.8% | 12.8% | ||
| Q3 25 | 24.8% | 15.9% | ||
| Q2 25 | 26.5% | 14.2% | ||
| Q1 25 | 24.3% | 12.8% | ||
| Q4 24 | 22.7% | 12.7% | ||
| Q3 24 | 23.9% | 14.9% | ||
| Q2 24 | 20.3% | 14.5% |
每股收益（稀释后）IDXXROL
| Q1 26 | — | $0.22 | ||
| Q4 25 | $3.09 | $0.24 | ||
| Q3 25 | $3.40 | $0.34 | ||
| Q2 25 | $3.63 | $0.29 | ||
| Q1 25 | $2.96 | $0.22 | ||
| Q4 24 | $2.62 | $0.22 | ||
| Q3 24 | $2.80 | $0.28 | ||
| Q2 24 | $2.44 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.1M | $116.5M |
| 总债务越低越好 | $450.0M | $650.6M |
| 股东权益账面价值 | $1.6B | $1.4B |
| 总资产 | $3.4B | $3.2B |
| 负债/权益比越低杠杆越低 | 0.28× | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资IDXXROL
| Q1 26 | — | $116.5M | ||
| Q4 25 | $180.1M | $100.0M | ||
| Q3 25 | $208.2M | $127.4M | ||
| Q2 25 | $164.6M | $123.0M | ||
| Q1 25 | $164.0M | $201.2M | ||
| Q4 24 | $288.3M | $89.6M | ||
| Q3 24 | $308.6M | $95.3M | ||
| Q2 24 | $401.6M | $106.7M |
总债务IDXXROL
| Q1 26 | — | $650.6M | ||
| Q4 25 | $450.0M | $486.1M | ||
| Q3 25 | — | $485.7M | ||
| Q2 25 | — | $485.3M | ||
| Q1 25 | — | $485.5M | ||
| Q4 24 | $617.8M | $395.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益IDXXROL
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | $1.6B | $1.5B | ||
| Q2 25 | $1.5B | $1.4B | ||
| Q1 25 | $1.4B | $1.4B | ||
| Q4 24 | $1.6B | $1.3B | ||
| Q3 24 | $1.6B | $1.3B | ||
| Q2 24 | $1.6B | $1.2B |
总资产IDXXROL
| Q1 26 | — | $3.2B | ||
| Q4 25 | $3.4B | $3.1B | ||
| Q3 25 | $3.4B | $3.2B | ||
| Q2 25 | $3.3B | $3.2B | ||
| Q1 25 | $3.2B | $2.9B | ||
| Q4 24 | $3.3B | $2.8B | ||
| Q3 24 | $3.4B | $2.8B | ||
| Q2 24 | $3.4B | $2.8B |
负债/权益比IDXXROL
| Q1 26 | — | 0.47× | ||
| Q4 25 | 0.28× | 0.35× | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | 0.39× | 0.30× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $355.8M | $118.4M |
| 自由现金流经营现金流 - 资本支出 | $326.3M | $111.2M |
| 自由现金流率自由现金流/营收 | 29.9% | 12.3% |
| 资本支出强度资本支出/营收 | 2.7% | 0.8% |
| 现金转化率经营现金流/净利润 | 1.43× | 1.10× |
| 过去12个月自由现金流最近4个季度 | $1.1B | $621.1M |
8季度趋势，按日历期对齐
经营现金流IDXXROL
| Q1 26 | — | $118.4M | ||
| Q4 25 | $355.8M | $164.7M | ||
| Q3 25 | $402.3M | $191.3M | ||
| Q2 25 | $185.7M | $175.1M | ||
| Q1 25 | $238.0M | $146.9M | ||
| Q4 24 | $262.0M | $188.2M | ||
| Q3 24 | $220.1M | $146.9M | ||
| Q2 24 | $248.3M | $145.1M |
自由现金流IDXXROL
| Q1 26 | — | $111.2M | ||
| Q4 25 | $326.3M | $159.0M | ||
| Q3 25 | $371.2M | $182.8M | ||
| Q2 25 | $151.6M | $168.0M | ||
| Q1 25 | $207.9M | $140.1M | ||
| Q4 24 | $232.8M | $184.0M | ||
| Q3 24 | $192.0M | $139.4M | ||
| Q2 24 | $215.0M | $136.4M |
自由现金流率IDXXROL
| Q1 26 | — | 12.3% | ||
| Q4 25 | 29.9% | 17.4% | ||
| Q3 25 | 33.6% | 17.8% | ||
| Q2 25 | 13.7% | 16.8% | ||
| Q1 25 | 20.8% | 17.0% | ||
| Q4 24 | 24.4% | 22.1% | ||
| Q3 24 | 19.7% | 15.2% | ||
| Q2 24 | 21.4% | 15.3% |
资本支出强度IDXXROL
| Q1 26 | — | 0.8% | ||
| Q4 25 | 2.7% | 0.6% | ||
| Q3 25 | 2.8% | 0.8% | ||
| Q2 25 | 3.1% | 0.7% | ||
| Q1 25 | 3.0% | 0.8% | ||
| Q4 24 | 3.1% | 0.5% | ||
| Q3 24 | 2.9% | 0.8% | ||
| Q2 24 | 3.3% | 1.0% |
现金转化率IDXXROL
| Q1 26 | — | 1.10× | ||
| Q4 25 | 1.43× | 1.41× | ||
| Q3 25 | 1.47× | 1.17× | ||
| Q2 25 | 0.63× | 1.24× | ||
| Q1 25 | 0.98× | 1.40× | ||
| Q4 24 | 1.21× | 1.78× | ||
| Q3 24 | 0.95× | 1.07× | ||
| Q2 24 | 1.22× | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
ROL
暂无分部数据
